Literature DB >> 11744023

Effects of A(3) adenosine receptor activation and gene knock-out in ischemic-reperfused mouse heart.

Glenn J Harrison1, Rachael J Cerniway, Jason Peart, Stuart S Berr, Kevin Ashton, Sara Regan, G Paul Matherne, John P Headrick.   

Abstract

OBJECTIVES: To characterize effects of A(3) adenosine receptor (A(3)AR) activation and gene knock-out on responses to ischemia-reperfusion in mouse heart.
METHODS: Perfused hearts from wild-type and A(3)AR gene knock-out (A(3)AR KO) mice were subjected to 20 min ischemia and 30 min reperfusion. Functional responses were assessed and changes in energy metabolism and cytosolic pH monitored via 31P-NMR spectroscopy.
RESULTS: Selective A(3)AR agonism with 100 nM 2-chloro-N(6)-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (chloro-IB-MECA) enhanced post-ischemic contractile recovery without altering contracture development in wild-type hearts, an effect unrelated to non-selective activation of A(1) or A(2) adenosine receptors. Chloro-IB-MECA also improved recovery in hearts overexpressing A(1)ARs. Paradoxically, post-ischemic recovery was enhanced by A(3)AR KO. Developed pressure, +dP/dt, and -dP/dt all recovered to higher levels in A(3)AR KO (70-80% of pre-ischemia) vs. wild-type hearts (45-50% of pre-ischemia) (P<0.05). Enhanced recovery was unrelated to recoveries of ATP, phosphocreatine (PCr), inorganic phosphate (P(i)), energy state ([ATP]/[ADP] x [P(i)], DeltaG(ATP)) or cytosolic pH.
CONCLUSIONS: Selective A(3)AR activation is cardioprotective in wild-type hearts and hearts overexpressing A(1)ARs, yet A(3)AR gene deletion generates an ischemia-tolerant phenotype without altering energy metabolism or pH. This may be due to compensatory changes or undefined genotypic differences in A(3)AR KO vs. wild-type hearts.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11744023     DOI: 10.1016/s0008-6363(01)00424-2

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  16 in total

Review 1.  Adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

Review 2.  Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology.

Authors:  S Jamal Mustafa; R Ray Morrison; Bunyen Teng; Amir Pelleg
Journal:  Handb Exp Pharmacol       Date:  2009

Review 3.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

4.  Ability of CP-532,903 to protect mouse hearts from ischemia/reperfusion injury is dependent on expression of A3 adenosine receptors in cardiomyoyctes.

Authors:  Tina C Wan; Akihito Tampo; Wai-Meng Kwok; John A Auchampach
Journal:  Biochem Pharmacol       Date:  2019-01-30       Impact factor: 5.858

5.  A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs.

Authors:  John A Auchampach; Zhe-Dong Ge; Tina C Wan; Jeannine Moore; Garrett J Gross
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-04-10       Impact factor: 4.733

Review 6.  Adenosine receptor subtypes and the heart failure phenotype: translating lessons from mice to man.

Authors:  Arthur M Feldman; Ellina Cheksis-Feiner; Eman Hamad; Tung Chan
Journal:  Trans Am Clin Climatol Assoc       Date:  2011

7.  Overexpression of A(3) adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts.

Authors:  Heather R Cross; Elizabeth Murphy; Richard G Black; John Auchampach; Charles Steenbergen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-06-20       Impact factor: 4.733

8.  Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor.

Authors:  Richard G Black; Yiru Guo; Zhi-Dong Ge; Sidney S Murphree; Sumanth D Prabhu; W Keith Jones; Roberto Bolli; John A Auchampach
Journal:  Circ Res       Date:  2002-07-26       Impact factor: 17.367

Review 9.  Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics.

Authors:  K Janes; A M Symons-Liguori; K A Jacobson; D Salvemini
Journal:  Br J Pharmacol       Date:  2016-03-06       Impact factor: 8.739

10.  Behavioral characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic neurodegeneration.

Authors:  Irina M Fedorova; Marlene A Jacobson; Anthony Basile; Kenneth A Jacobson
Journal:  Cell Mol Neurobiol       Date:  2003-06       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.